Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Petra Stieber

Showing results (1-10 of 83) with videos related to

Pageof 9
Sort By:
Cancer Biomarkers : Section a of Disease Markers|July 28, 2010
Circulating apoptotic markers in the management of non-small cell lung cancerStefan Holdenrieder, Petra Stieber
Critical Reviews in Clinical Laboratory Sciences|December 25, 2008
Clinical use of circulating nucleosomesStefan Holdenrieder, Petra Stieber
Cancer Biomarkers : Section a of Disease Markers|July 28, 2010
Estimation of prognosis by circulating biomarkers in patients with non-small cell lung cancerStefan Holdenrieder, Dorothea Nagel, Petra Stieber
Cancer Biomarkers : Section a of Disease Markers|July 28, 2010
Relevance of circulating biomarkers for the therapy monitoring and follow-up investigations in patients with non-small cell lung cancerVivian Barak, Stefan Holdenrieder, Benjamin Nisman, et al.
Anticancer Research|July 2, 2010
Long-term stability of circulating nucleosomes in serumStefan Holdenrieder, Joachim Von Pawel, Dorothea Nagel, et al.
Onkologie|February 5, 2005
Re-evaluation of HER2 status in metastatic breast cancer and tumor-marker guided therapy with vinorelbine and trastuzumabHans-Joachim Stemmler, Petra Stieber, Dorit Lässig, et al.
Therapeutische Umschau. Revue Therapeutique|September 16, 2008
[Selective application of tumor markers PSA]Maciej Kwiatkowski, Petra Stieber, Andreas R Huber, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|September 12, 2012
Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapyNikolaus Kohles, Dorothea Nagel, Dietrich Jüngst, et al.
Oncology|August 11, 2006
Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancerStefan Boeck, Petra Stieber, Stefan Holdenrieder, et al.
Anticancer Research|July 22, 2005
Circulating nucleosomes and cytokeratin 19-fragments in patients with colorectal cancer during chemotherapyStefan Holdenrieder, Lubos Holubec, Ondrej Topolcan, et al.
Pageof 9

Showing results (1-10 of 83) with videos related to

Sort By:
Pageof 9
Cancer Biomarkers : Section a of Disease Markers|July 28, 2010
Circulating apoptotic markers in the management of non-small cell lung cancerStefan Holdenrieder, Petra Stieber
Critical Reviews in Clinical Laboratory Sciences|December 25, 2008
Clinical use of circulating nucleosomesStefan Holdenrieder, Petra Stieber
Cancer Biomarkers : Section a of Disease Markers|July 28, 2010
Estimation of prognosis by circulating biomarkers in patients with non-small cell lung cancerStefan Holdenrieder, Dorothea Nagel, Petra Stieber
Cancer Biomarkers : Section a of Disease Markers|July 28, 2010
Relevance of circulating biomarkers for the therapy monitoring and follow-up investigations in patients with non-small cell lung cancerVivian Barak, Stefan Holdenrieder, Benjamin Nisman, et al.
Anticancer Research|July 2, 2010
Long-term stability of circulating nucleosomes in serumStefan Holdenrieder, Joachim Von Pawel, Dorothea Nagel, et al.
Onkologie|February 5, 2005
Re-evaluation of HER2 status in metastatic breast cancer and tumor-marker guided therapy with vinorelbine and trastuzumabHans-Joachim Stemmler, Petra Stieber, Dorit Lässig, et al.
Therapeutische Umschau. Revue Therapeutique|September 16, 2008
[Selective application of tumor markers PSA]Maciej Kwiatkowski, Petra Stieber, Andreas R Huber, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|September 12, 2012
Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapyNikolaus Kohles, Dorothea Nagel, Dietrich Jüngst, et al.
Oncology|August 11, 2006
Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancerStefan Boeck, Petra Stieber, Stefan Holdenrieder, et al.
Anticancer Research|July 22, 2005
Circulating nucleosomes and cytokeratin 19-fragments in patients with colorectal cancer during chemotherapyStefan Holdenrieder, Lubos Holubec, Ondrej Topolcan, et al.
Pageof 9